A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ITEM 1. BUSINESS Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (Bio-Techne, we, our, us or the Company), develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. Our broad product portfolio and application expertise enables scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. We manage the business in two operating segments – our Protein Sciences segment and our Diagnostics and Spatial Biology segment. Our Protein Sciences segment is a leading developer and manufacturer of high-quality biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.2B | 1.2B | 1.2B | 1.1B | 1.1B | 931M |
| Net Income | 81M | 73M | 168M | 285M | 272M | 140M |
| EPS | $0.53 | $0.46 | $1.05 | $1.76 | $1.66 | $0.87 |
| Free Cash Flow | 223M | 257M | 236M | 216M | 280M | 308M |
| ROIC | 4.3% | 3.7% | 8.4% | 11.9% | 15.0% | 13.3% |
| Gross Margin | 65.2% | 64.8% | 66.4% | 67.7% | 68.4% | 68.0% |
| Debt/Equity | 0.13 | 0.18 | 0.15 | 0.18 | 0.16 | 0.23 |
| Dividends/Share | $0.32 | $0.32 | $0.32 | $0.32 | $0.32 | $0.31 |
| Operating Income | 117M | 102M | 207M | 299M | 297M | 237M |
| Operating Margin | 9.6% | 8.4% | 17.8% | 26.3% | 26.8% | 25.5% |
| ROE | 4.0% | 3.7% | 8.1% | 14.5% | 16.0% | 9.0% |
| Shares Outstanding | 156M | 160M | 160M | 162M | 164M | 162M |
BIO-TECHNE Corp passes 5 of 9 quality checks, suggesting mixed fundamentals.
BIO-TECHNE Corp trades at 125.1x trailing earnings, compared to its 15-year median P/E of 47.1x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 35.8x vs a median of 48.9x. The company's 5-year average ROIC is 10.4% with a gross margin of 67.1%. Total shareholder yield (dividends + buybacks) is 2.8%. At current prices, the estimated annualized return to fair value is +6.9%.
BIO-TECHNE Corp (TECH) has a current P/E ratio of 125.1, compared to its historical median P/E of 47.1. The stock is currently considered Expensive based on its historical valuation range.
BIO-TECHNE Corp (TECH) has a 5-year average return on invested capital (ROIC) of 10.4%. This indicates solid capital allocation.
BIO-TECHNE Corp (TECH) has a market capitalization of $9.0B. It is classified as a mid-cap stock.
Yes, BIO-TECHNE Corp (TECH) pays a dividend with a trailing twelve-month yield of 0.55%. The company also returns capital through share buybacks, with a buyback yield of 2.22%.
Based on historical P/E analysis, BIO-TECHNE Corp (TECH) appears expensive. The current P/E of 125.1 is 166% above its historical median of 47.1. The estimated fair value CAGR (P/E method) is -2.3%.
BIO-TECHNE Corp (TECH) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
BIO-TECHNE Corp (TECH) reported annual revenue of $1.2 billion in its most recent fiscal year, based on SEC EDGAR filings.
BIO-TECHNE Corp (TECH) has a net profit margin of 6.0%. This is a modest margin.
BIO-TECHNE Corp (TECH) generated $257 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
BIO-TECHNE Corp (TECH) has a debt-to-equity ratio of 0.18. This indicates a conservatively financed balance sheet.
BIO-TECHNE Corp (TECH) reported earnings per share (EPS) of $0.46 in its most recent fiscal year.
BIO-TECHNE Corp (TECH) has a return on equity (ROE) of 3.7%. This indicates moderate shareholder returns.
BIO-TECHNE Corp (TECH) has a 5-year average gross margin of 67.1%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for BIO-TECHNE Corp (TECH), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
BIO-TECHNE Corp (TECH) has a book value per share of $12.03, based on its most recent annual SEC filing.